Phio Pharmaceuticals (PHIO) Profit After Tax (2011 - 2026)

Phio Pharmaceuticals (PHIO) has 16 years of Profit After Tax data on file, last reported at -$4.0 million in Q1 2026.

• Quarterly Profit After Tax fell 126.29% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.3 million (down 52.7% YoY) and the FY2024 annual result came in at -$7.2 million, up 33.96% from the prior year.
• Profit After Tax slipped to -$4.0 million in Q1 2026, from -$2.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.5 million in Q3 2024 to a low of -$4.0 million in Q1 2026.
• A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax surged 45.18% — and 2026, when it slumped 126.29%.
• Tracing PHIO's Profit After Tax over 5 years: stood at -$2.7 million in 2022, then jumped by 30.61% to -$1.9 million in 2023, then rose by 14.2% to -$1.6 million in 2024, then tumbled by 47.11% to -$2.4 million in 2025, then slumped by 67.35% to -$4.0 million in 2026.
• The last three Profit After Tax figures came in at -$4.0 million (Q1 2026), -$2.4 million (Q3 2025), and -$2.2 million (Q2 2025), per Business Quant data.